Objective: The aim of this study was to evaluate the predictive value of a single or combination of biomarker(s) for histopathologic non-response to neoadjuvant chemoradiation in esophageal cancer. Summary of Background Data: Patients without response to neoadjuvant chemoradiation for esophageal cancer have no prognostic benefits, but experience time delays and risk side effects. Methods: Inclusion criteria for this prospective diagnostic study were patients with cT3,Nx,M0, esophageal squamous cell or adenocarcinoma and planned neoadjuvant chemoradiation (5-fluorouracil, cisplatin, 40Gy) followed by 2-field transthoracic esophagectomy. From pretherapeutic endoscopic tumor biopsies, ERCC1 rs11615 single-nucleotide polymorphism (ERCC1-SNP) and a combination of gene expression marker mRNA (ERCC1, DPYD, ERBB2) were analyzed. ERCC1-SNP was subdifferentiated into homozygous C-allele (CC) and T-allele (TT), and heterozygous C/T carriers. The primary endpoint was the prediction of histopathological minor response (10% vital tumor cells in the primary tumor) relative to marker levels. Results: From 2009 until 2013, 320 patients were screened, and 85 patients (SCC n ¼ 29, AC n ¼ 56) were included in the study. Forty-one patients (48%) had major response with 3-year survival rate (3-YSR) of 57% compared with 44 patients with minor response and 3-YSR of 25% (P ¼ 0.001). Patients with ERCC1-SNP CC (n ¼ 8) and TT (n ¼ 37) had similar rates of minor response of 70% and 75%, and a positive predictive value (PPV) of 71% [95% confidence interval (CI 56%-84%)]. PPV increased to 89% (95% CI 73%-96%) when ERCC1-SNP was combined with mRNA markers. Conclusion: ERCC1-SNP in combination with mRNA ERCC1, DPYD, and ERBB2 from pretherapeutic endoscopic biopsies can predict minor response to chemoradiation, as a basis for individualized therapy of advanced esophageal cancer.
E sophageal squamous cell carcinoma (SCC) and adenocarcinoma (AC) are common malignancies worldwide. 1 The poor prognosis of patients with advanced tumor stage particularly encouraged assessment of neoadjuvant treatment strategies to improve patients' survival. 2, 3 However, only patients with major histopathologic response clearly benefit from neoadjuvant treatment. 4, 5 Approximately half of patients show only minor histopathologic response after a lasting chemoradiation 3 ; thus, these patients should be identified before starting treatment. Clinical diagnostics like endoscopy, computed tomography, or positron emissions tomography have failed to predict response. 6, 7 Other researchers have developed a nomogram to predict complete response after chemoradiation. They used patient-related factors like sex, comorbidity, and tumor histology. The results showed reasonable predictive power. 8 Potential predictive factors in the neoadjuvant therapy of esophageal cancer have been recently characterized with innovative molecular-based technologies. [9] [10] [11] [12] These factors include growth factor receptors, enzymes of angiogenesis, tumor suppressor genes, cell cycle regulators, as well as enzymes involved in the DNA repair system, in apoptosis, and in degradation of the extracellular matrix. 9 Other studies have analyzed microRNA for the prediction of response to neoadjuvant chemoradiation of advanced esophageal cancer. 13, 14 Our group's research focus has been the characterization of predictive factors for neoadjuvant therapy of esophageal cancer. [15] [16] [17] [18] One of our most recent projects investigated gene polymorphism of excision repair cross-complementing 1 (ERCC1) to predict response to neoadjuvant chemoradiation [cisplatin, 5-fluorouracil (FU), 40 Gy] in advanced esophageal cancer. 19, 20 In another retrospective study, we analyzed a panel of molecular markers and found that the combination of several markers improved the accuracy of the prediction up to 85%. While testing the single genes alone, the accuracy was not better than 66%. Measuring the expression of only 3 genes [dihydropyrimidine dehydrogenase (DPYD), excision repair cross complementing 1 (ERCC1), and human epidermal growth factor receptor-2 ERBB2 (also called HER2/neu)] enabled approximately 73% accuracy for prediction of major response. 21 This is the rational for combining these markers.
The results of these retrospective studies are mostly promising, but prospective studies are needed to validate these markers in multimodal therapy of esophageal cancer.
Thus, the aim of this study was to evaluate prospectively the predictive value of ERCC1-SNP rs11615 as well as the 3-gene combination for therapeutic response to induction chemoradiation in esophageal carcinoma.
METHODS

Study Design
The study was planned as a prospective, nonrandomized diagnostic study based on molecular markers for the prediction of response to neoadjuvant chemoradiation (NCT00628368).
Inclusion criteria were patients older than 18 years with advanced (cT3,Nx,M0), resectable esophageal AC or SCC.
Exclusion criteria were lack of informed consent, previous radiotherapy and/or chemotherapy, second malignancy, or clinically relevant coronary artery or pulmonary disease, renal or hepatic dysfunction.
The primary endpoint was the predictive value for minor histopathological response to chemoradiation therapy (10% vital tumor cells in the primary tumor ¼ MiHR) in relation to ERCC1 rs11615 polymorphism and the previously defined marker panel. 20, 21 Study Population, Demographic Data, and Neoadjuvant Therapy From September 2009 until March 2013, 320 patients with esophageal cancer were screened for this study. The flowchart of excluded patients is shown in Figure 1 . Finally, 85 patients were included. None of the patients had undergone previous radiotherapy and/or chemotherapy. Briefly, cisplatin (20 mg/m 2 /d) was administered as a short-term infusion on days 1 to 5, and 5-FU (1000 mg/m 2 / d) was given as continuous infusion over 24 hours on days 1 to 5. Radiation was delivered in daily fractions of 1.8 Gy to a total dose of 40 Gy using a multiple field technique. Clinical restaging by endoscopy and computer tomography was performed in all patients to exclude distant metastasis. Response of the primary tumor was not quantified. Standardized transthoracic en-bloc esophagectomy with 2-field lymphadenectomy was performed about 6 weeks after completion of chemoradiation. Clinical data are summarized in Table 1 . Informed consent was obtained from each patient and the scientific protocol was approved by the local ethics committee.
Histopathologic Response Classification
The histopathologic work-up of the entire primary tumor was performed as previously described. 5 Therapy-induced changes included reactive changes such as necrosis, fibrosis, foamy histiocytes, and giant cell reactions. 22 The degree of histomorphologic regression of the primary tumor was classified into 4 categories (Cologne Regression Scale): grade 1, complete response; grade 2, <10% vital residual tumor cells (VRTCs); grade 3, 10% to 50% VRTCs; and grade 4, >50% VRTCs. 2, 5 This analysis was performed by experienced staff pathologists blinded to all other clinical data. Because of prognostic implications, regression grades 1 and 2 were classified as major histomorphologic response (MaHR) versus grades 3 and 4, which were categorized as minor histopathologic response (MiHR). Lymph node status was classified according to the 7th edition of the TNMclassification. 23 
Allelic Discrimination by TaqMan SNP Genotyping Assays
Genomic DNA was extracted from 2-mL serum with the QIAamp UltraSens virus kit (Qiagen, Germany). Ten nanograms of genomic DNA were used as template for SNP genotyping with real-time polymerase chain reaction (PCR) by TaqMan 7900HT (Life Technologies, Germany). PCR conditions have been previously described. 19 SNP analysis involves discrimination of single nucleotide changes when applying 2 allele-specific probes labeled with different fluorophores. ERCC1-SNP was subdifferentiated into homozygous C-allele (CC) and T-allele (TT), and heterozygous C/T carriers.
Quantification of mRNA Expression by TaqMan Low-density Arrays
Before therapy, endoscopic biopsies were obtained during routine staging esophagogastroscopy. Tissue samples from esophageal cancers and corresponding normal tissues far from the tumor were immediately snap-frozen in liquid nitrogen and stored at -808C.
Total cellular RNA (0.5 mg) was reverse-transcribed using oligo(dT) 18 primers and Moloney murine leukemia virus (MMLV) reverse transcriptase (RT-for-PCR kit TM , Takara Bio Europe Clontech, France).
The amount of mRNA of a specific gene was measured by its threshold cycle (Ct), and normalized to that of 18S rRNA as an n-fold difference (DCt). The expression of genes of interest in each tumor sample was compared with the amount of a calibrator sample, the FIGURE 1. Flow chart of study patients. A total of 320 patients with esophageal cancer were screened for this study. Eighty-nine were eligible for palliative treatment only, and another 95 patients underwent primary surgery. Neoadjuvant therapy was planned for 136 patients with cT3,pNx,M0 esophageal cancer. Forty-six patients underwent preoperative chemotherapy or a different regimen of chemoradiation initiated by external physicians. The remaining 90 patients were treated with chemoradiation according to the described protocol. Five patients were excluded because of a lack of informed consent. CTx indicates chemotherapy; OP, surgical therapy; RTx/CTx, chemoradiation.
corresponding normal sample (DDCt). Customized 384-well lowdensity arrays for PCR amplification were designed using individual primers for genes of interest, chosen and purchased from the assays on demand gene-expression products (Life Technologies, Germany) including Hs00157415 (ERCC1), Hs00559278 (DPYD), and Hs00170433 (c-erBB-2). Handling and cycling conditions have been previously described. 21 
Statistical Analysis
According to our previous studies, we expected in the ERCC1 C/T group (40% of the patients) about 35% MiHR and 70% in the homocygous groups. The calculated sample size (a ¼ 0.05, ß ¼ 0.20) to approve this difference was 77 patients. SNP data were analyzed with x 2 analysis or Fisher exact test. The Mann-Whitney U test was used to compare gene expressions of samples from patients with major versus minor response. The diagnostic performance of the test is reported as predictive values. Classification and regression trees were used to define cutoff values for the mRNA expression using an earlier data set (SPSS Software Version 20.0, SPSS Inc, Chicago, IL). The diagnostic performance or accuracy of the molecular markers to discriminate minor responders from major responders is evaluated using receiver-operating characteristic (ROC) curve analysis. In addition, we used the ROC curves of the different marker panels to compare their diagnostic performance. Kaplan-Meier plots were used to characterize survival distribution. The 3-year survival rate (3-YSR) with 95% confidence interval (95% CI) was used as a point estimation of prognosis. The log-rank test was applied to evaluate survival differences. Postoperative mortality was included in prognostic calculations. The level of significance was set to P < 0.05.
Survival Analysis
RESULTS
Neoadjuvant Treatment and Survival in Esophageal Carcinoma
The present study included 85 patients. About half of these patients (n ¼ 44, 51%) showed minor response by the primary tumor or progression during chemoradiation ( Table 1) . Patients with distant metastasis (M1, n ¼ 6) detected during restaging underwent no further surgical procedures. The median survival rate of these patients was 8 months (95% CI 5-18months) after diagnosis. The 30-day postoperative mortality was 1.2%. Univariate analysis of prognosis showed a 3-YSR of 40% for all patients. Patients with major response by the primary tumor and without lymph node metastasis (LNM) had the best prognosis with 3-YSR of 73% (Table 1 ). In contrast, patients with minor response by the primary tumor and LNM had 3-YSR of only 20% ( Table 1 ). The comparison between SCC and AC is presented in Table 3 . 
Genotype Distribution, Subject Characteristics, and Response
Distribution of ERCC1-SNP was CC: n ¼ 8 (10%), TT: n ¼ 37 (43%), C/T: n ¼ 40 (47%). Correlation between ERCC1-SNP variants, tumor characteristics, and regression grades is depicted in Table 2 .
ERCC1-SNP correlated with response to neoadjuvant therapy by the primary tumor (P < 0.001). Twenty-six patients with TT genotype and 6 patients with CC genotype comprised 73% of the 44 minor responders; only 11 TT and 2 CC genotype patients showed major response. In contrast, heterozygous C/T genotype was present in 68% of all patients with major response ( Table 2) . Patients with homozygous TT or CC genotypes also showed more frequent LNM or distant metastases (67%) versus heterozygous C/T genotype (33%) (P ¼ 0.020).
3-YSR for patients with homozygous TT genotype was 18% (95% CI 5%-37%), with CC genotype was 38% (95% CI 9%-67%), and with heterozygous C/T was 64% (95% CI 46%-77%) (P < 0.001) (Fig. 2) . The comparison between SCC and AC is presented in Table 3 .
Predictive Power of Molecular Markers for Minor Response
For MiHR, the homozygous ERCC1-SNP variants CC and TT combined yielded a positive predictive value (PPV) of 71% (95% CI 56%-84%), and a negative predictive value (NPV) of 70% (95% CI 54%-83%) with a sensitivity of 73%, specificity of 68%, and an accuracy of 71%.
Expression of the 3 genes (DPYD, ERBB2, and ERCC1) was higher, but not significantly so, in cases with minor versus major response (P ¼ 0.456, P ¼ 0.061, and P ¼ 0.123). The association between gene expression and therapy response in the primary tumor is depicted in Figure 3 .
To improve the diagnostic accuracy for the prediction of minor response to chemoradiation, we used the results of decision trees analysis of an earlier dataset including the mRNA expression cutoff values for ERCC1 of >1.06, ERBB2 <0.88, and DPYD <0.57. Patients with heterocygous ERCC1-SNP C/T were classified as predicted MaHR (n ¼ 40). In the group of patients with homozygous ERCC1-SNP TT or CC (n ¼ 45), the mRNA expression for the different marker was tested. Using this algorithm, 9 of 13 cases mistakenly predicted to have MiRH had been correctly predicted as MaHR.
For the entire study group, the PPV for MiHR improved to 89% (95% CI 73%-97%) and the NPV to 74% (95% CI 60%-85%) with a sensitivity of 70%, specificity of 90%, and an accuracy of 80%. Figure 4 shows the comparison between the ROC curves for ERCC1-SNP and the combination of the molecular markers. The improvement of diagnostic performance was 10.3% (95% CI 2.5%-17.9%, P ¼ 0.009). The comparison between SCC and AC is presented in Table 3 .
DISCUSSION
The results of this prospective diagnostic study support the data of previous retrospective studies, which identified ERCC1 rs11615 single-nucleotide polymorphisms as an indicator for nonresponse to a common 5-fluorouracil, cisplatin, and radiationbased neoadjuvant therapy. 19, 20 Several studies have shown that the prognosis of patients with advanced esophageal cancer and minor response after preoperative chemoradiation is not different from those patients undergoing primary surgery. 3, 24 Personalized medicine helps to select optimal treatment maximizing benefit and minimizing harm. Therefore, it is necessary to introduce validated research results into clinical use.
Cisplatin is a platinum analog commonly used for many cancers. It binds to DNA, forms DNA adducts, and inhibits DNA replication. 25 DNA repair mechanisms play an important role for response to cisplatin. ERCC1 is part of the nucleotide excision repair (NER) complex involved in repair of radiation and platinum-induced inter and intrastrand crosslinks. Since efficient DNA repair capacity seems to be a critical mechanism of resistance to platinum drugs and radiation, we conclude that the NER pathway is important for therapy outcome. 26 ERCC1-SNP rs11615 encoded by codon 118 is associated with reduced ERCC1 mRNA expression. The single nucleotide change of C to T represents a silent mutation converting (AAC) to (AAT), both coding for the same amino acid asparagine. 27 The unfavorable codon usage (AAT) is hypothesized to lead to decreased expression impairing DNA repair activity. 28 Using this ERCC1-SNP, we were able to predict the risk of MiHR by the primary tumor in about 70% of patients. Thus, a patient with the TT or CC genotype is at high risk to suffer the negative consequences of chemoradiation without prognostic benefit. This corresponds to the results of earlier retrospective studies. Quixing et al 29 performed a meta-analysis assessing the predictive value of ERCC1 polymorphism. Nine studies were available investigating the correlation of the ERCC1-SNP rs11615 and neoadjuvant therapy. Subgroup analysis of 5 studies with esophageal cancer patients demonstrated that patients carrying the homozygous CC-TT genotypes presented a worse response rate than subjects carrying heterogeneous C/T genotype (OR ¼ 0.228, 95% CI 0.125-0.418).
The functional impact of this polymorphism on gene expression and platinum sensitivity has not been well explained. Gao et al 30 studied ERCC1 cDNA clones carrying either the C or T allele introduced into an ERCC1 deficient cell line. In both cases, ERCC1 mRNA and protein expression levels increased upon cisplatin treatment, peaking at 4 hours post-treatment. There were no differences between the wild type and the 2 alleles (P > 0.05). The authors concluded that ERCC1-SNP rs11615 itself is not related to the phenotypic differences in ERCC1 expression. In addition, the response to neoadjuvant therapy depends on the combination of chemotherapy agents and radiation.
Using ERCC1-SNP alone in clinical practice would result in approximately 30% of patients who would achieve major response not receiving treatment. Therefore, we conclude that this single molecular marker for prediction of response to chemotherapy is not accurate enough for clinical use. Other authors have shown the heterogeneity of molecular markers for response prediction in esophageal cancer. 30, 31 In an earlier study, we found that the combination of several molecular markers improves prediction accuracy. 21 We combined the ERCC1-SNP with 3 molecular markers (ERCC1, ERBB2, and DPYD), and the PPV for minor response by the primary tumor improved to 89%.
There are several retrospective studies confirming the predictive power of these tested markers. 16, 18, [32] [33] [34] DPYD is the ratelimiting enzyme in 5-FU catabolism and mRNA expression of ERCC1 is involved in the repair of platin agents. 17 ERBB2 is a member of the type I growth factor receptor gene family, which leads to receptor kinase activity. Altered expression of receptor tyrosine kinases has a critical role in cancer pathogenesis. 16 To introduce the results obtained here into routine clinical practice with patients, first, a blood test determining ERCC1-SNP must be carried out. In cases of heterogeneous C/T, the neoadjuvant therapy defined here may be offered. In cases of homozygous CC or TT, additional markers should be determined to reduce the risk of false-negative predictions.
In the present study, mRNA expression assays were performed from biopsies of tumor and normal tissue. For routine clinical use, it would be preferable for these to be performed from liquid biopsies, 18, 34, 35 like those already performed for polymorphism.
Another weak point of our study is that the therapeutic concept changed because of the results of the CROSS-study. 24 Thus, adaptations of the marker panel required to maintain the predictive value must be further explored. Further limitations of this study are: this was a monocentric study and the results should be confirmed by other centers; the heterogeneity of molecular markers in different patient's population may be a problem; and the accuracy of the combination of these biomarkers is rather good, but it should be compared to recently published data of clinic variables. 8 
CONCLUSION
In summary, our findings strongly support the concept that ERCC1 gene polymorphisms are a host factor predictive for histopathological minor response to cisplatin/5-FU-based chemoradiation in esophageal carcinoma. ERCC1-SNP in combination with mRNA ERCC1, DPYD, and ERBB2 from pretherapeutic endoscopic biopsies can be used to predict minor response to chemoradiation, as a basis for individualized therapy of advanced esophageal cancer. The next step will be to test this combination in an independent cohort of patients followed by studies with marker-based treatment algorithm. Thank you for your interesting study on the response prediction to neoadjuvant chemoradiation using multiple biomarkers. This is an important topic that could lead to a more tailor-made treatment in patients with esophageal cancer.
I have several questions: First on the Methodology. Why did you select only T3Nx tumors in this study and not also T2Nx tumors, which together form 1 stage with similar prognosis in the UICC classification IIb and III?
Second, the definition of your primary endpoint is rather arbitrary. You dichotomized the general tumor regression score into < or >10% viable tumor cells. Why did you chose to do this and did you not look more precisely into the various grades including also 0% tumor cells, 10% to 50%, and >50%?
Third, in your study, the squamous cell carcinoma had a complete response rate of only 24% and adenocarcinoma 14%. These response percentages are much lower than in the CROSS trial where 49% was found for squamous cell carcinoma and 23% for adenocarcinoma. Furthermore, the makers that you tested did not show a significant difference in major and minor responses in the 2 tumor types (Table 3 ). This may limit the applicability. How do you explain this?
Finally, there is a large heterogeneity of molecular marker signatures to predict response to neoadjuvant treatment. This may limit the reproducibility and consequently the clinical use of your results. What would be your next step toward the validation of your results?
Response From H. Schmidt (Cologne, Germany):
Prof. Hillegersberg, thank you for your interesting questions. First, I think we all agree on recommending neoadjuvant treatment for clinical T3 esophageal cancers. However, there is no clear data that show a significant benefit of neoadjuvant therapy in clinical T2cancers regarding overall survival. This was also recently shown by the French esophageal working group FREGAT, which analyzed over 300 cT2-cancer patients and found no difference in overall survival between multimodal treated patients and those who did undergo primary surgery.
Second, that is a very good point. Today there are different competing regression scales available using different cutoff points for histopathologic response grading. In this study, we used our own Cologne histopathologic regression scale, which is in place for many years and very well established in our center and routinely used by our pathologists who are doing the analysis and the grading. Suppose you have 3 groups with no visible tumor versus one to 50% or >50% residual vital tumor cells. We think that you would underrepresent a subgroup of patients with 1% to 10% of residual vital tumor cells, which actually responded and therefore benefited from the treatment. Additionally, we showed that dividing into major and minor responders does have prognostic implications.
Third, I have to highlight that we did not use the CROSSregime in this cohort, as our study period began at the end of 2009. At that time only patients with an older treatment regime were included. For analysis purposes, we then did not include patients undergoing the CROSS-regime. I agree that the response rates are improved when administering the CROSS-regime. However, the cross trial does have its own limitations as there might be less advanced cancers also included in the cohort resulting in improved overall outcome. I think this is an explanation for the lower overall survival in this study than reported in the CROSS trial.
Finally, we differentiated for the ERCC1-SNP as well as for the mRNA expression for both histologies. We did not have any significant differences in this analysis. We had mRNA expression and upregulation in the adeno-as well as in the squamous cell group showing no differences at all. We also were able to show that the molecular markers had prognostic implications in both tumor types before. We did expect a difference, although we know that the squamous cell carcinomas show better response rates. However, in this cohort, we did not have any differences.
P.R. O'Connell (Dublin, Ireland):
Just a small question about the sampling of your tumor: How do you account for the heterogeneity within the tumor. How do you know that when you have taken a biopsy and it is positive or negative by your analysis whether that is a true reflection of the tumor or just a sampling issue.
Response From H. Schmidt (Cologne, Germany):
Prof. O'Connell, thank you for this important remark. We cannot be 100% certain that the biopsy is only from the tumor or that it reflects the mRNA expression of the whole tumor. During the routine primary endoscopy, biopsy samples were taken according to a standardized algorithm, with multiple biopsies from the tumor side as well as from normal corresponding tissue to compare. However, even with standardized algorithms and limited observer number, sampling errors cannot be completely excluded during the clinical routine.
C. Bruns (Cologne, Germany):
Could you explain again, why you chose the evaluation of the polymorphisms of the genes ERCC1 and DPD?
Response From H. Schmidt (Cologne, Germany):
We had done pilot studies before we did this trial. For the ERCC1-SNP, we have already shown good prognostic relevance for histopathological response after neoadjuvant treatment. Aim of this study was to verify these results in a prospective trial. The ERCC1-SNP is one of the very good described SNP for this cancer and we hypothesized that in combination with the mRNA-Expression of the ERCC1, ERBB2, and DPYD genes, the response prediction would further improve.
